AVIR at a glance
Atea Pharmaceuticals, Inc. (AVIR, SEC CIK 1593899) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Atea Pharmaceuticals, Inc. (AVIR) shares worth $116.4 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Polsky Bruce on November 19, 2026 of 8,750 shares at $4.03 per share.
- In the last 90 days, AVIR insiders reported 0 open-market purchases ($0) and 6 open-market sales ($320K) on Form 4, a net sale of $320K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$320K
- 13F holders
- 25 funds
- $116.4M · +1 vs prior quarter
- Latest 8-K
- Nov 9, 2026
- Item 2.03 · Item 1.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no products approved or product sales generated
- Operating loss $34.0M vs $45.6M YoY, operating margin not applicable
- HCV R&D $17.4M vs $30.2M, strongest program; HEV R&D $2.7M vs $0
- Cash and investments $191.2M; nine-month operating cash use $112.3M vs $103.8M
- C-FORWARD results expected Q1 2027, FDA NDA submission targeted Q2 2027; funding expected into mid-2028
Risk Factors
- New debt facility: November 2026 Hercules agreement adds $65.0 million funded debt, floating-rate interest, and $200.0 million total commitments
- Liquidity risk: $105.0 million of undrawn capacity requires milestones, while $30.0 million remains at lenders’ discretion
- Regulatory pricing risk: September 2026 Globe regulation may require Medicare Part B rebates based on most-favored-nation pricing
- Clinical risk: C-FORWARD Phase 3 results remain critical, with topline results anticipated in first-quarter 2027
- Financial condition: Nine-month 2026 net loss reached $110.5 million, with accumulated deficit of $633.1 million
AI summary of the AVIR 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.03: Creation of a Direct Financial Obligation
- Item 2.03 points to Item 1.01 for details on Atea’s newly created financial obligation
- Investor impact depends on the referenced agreement’s payment terms, amount, maturity and purpose
Item 1.01: Entry into a Material Definitive Agreement
- Up to $200.0M senior secured financing, with $65.0M drawn at closing on November 6, 2026
- Floating interest rate at the greater of prime plus 2.35% or 9.35%, increasing financing costs
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 financial results announced for the three months ended September 30, 2026
- Press release contains the substantive financial results and accompanying company updates, filed as Exhibit 99.1
Item EX-99.1: Item EX-99.1
- C-BEYOND met primary and secondary endpoints, with BEM/RZR SVR 93.91% versus SOF/VEL 94.75% in 905 patients
- C-FORWARD fully enrolled with more than 880 patients across 17 countries, topline results expected early 2027
Item EX-99.1: Item EX-99.1
- C-BEYOND met non-inferiority: BEM/RZR SVR 93.9% vs 94.8% for SOF/VEL in 905 patients
- Eight-week BEM/RZR achieved 93.5% SVR in non-cirrhotic patients vs 94.6% for 12-week SOF/VEL
Item 2.02: Results of Operations and Financial Condition
- Press release reports Atea Pharmaceuticals’ financial results for the quarter ended June 30, 2026
- Exhibit 99.1 contains the underlying results and other company updates relevant to investors
AI summaries of AVIR 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for AVIR
Don't miss the next AVIR filing
- Alerts as it files. A push when AVIR files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut AVIR, by share count.
- Ask anything. An AI agent that reads every AVIR filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Lucidi Bruno | M | Nov 19, 2026 | 53,372 | $1.24 |
| Lucidi Bruno | M | Nov 19, 2026 | 53,372 | - |
| Polsky Bruce | Sell | Nov 19, 2026 | 8,750 | $4.03 |
| Lucidi Bruno | Sell | Nov 19, 2026 | 22,619 | $3.94 |
| Polsky Bruce | M | Nov 18, 2026 | 18,252 | - |
| Polsky Bruce | M | Nov 18, 2026 | 18,252 | $1.24 |
| Polsky Bruce | Sell | Nov 18, 2026 | 18,252 | $3.95 |
| Polsky Bruce | M | Nov 17, 2026 | 8,720 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Operating Income | -$164.2M | -$192.9M | -$180.9M | |
| Net Income | -$136.0M | -$168.4M | -$158.3M | |
| Balance Sheet | ||||
| Total Assets | $595.0M | $464.7M | $315.2M | |
| Equity | $555.2M | $438.9M | $275.4M | |
| ROE | -24.5% | -38.4% | -57.5% | |
| Per Share | ||||
| EPS | $-1.63 | $-2.00 | $-1.94 | |
| Cash Flow | ||||
| Operating CF | -$85.4M | -$135.5M | -$132.0M | |
Source: XBRL data in Atea Pharmaceuticals, Inc. (AVIR)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate AVIR share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $116.4M |
| Q2 2026 | 24 | $161.2M |
| Q1 2026 | 25 | $184.9M |
| Q4 2025 | 22 | $115.5M |
| Q3 2025 | 24 | $82.6M |
| Q2 2025 | 24 | $98.2M |
| Q1 2025 | 21 | $55.1M |
| Q4 2024 | 16 | $57.5M |
- BlackRock+341.5K (+4%)
- AQR Capital Management+246.0K (+99%)
- Bank of America Corp+27.1K (+33%)
- Vanguard Portfolio Management LLC+9.8K (+2%)
- D.E. Shaw & Co+8.3K (+2%)
- Two Sigma Investments−203.4K (-13%)
- Morgan Stanley−163.0K (-23%)
- Millennium Management−144.7K (-48%)
- Citadel Advisors LLC−142.4K (-91%)
- Vanguard Capital Management LLC−58.1K (-2%)
- M&T Bank+10.1K
- U.S. Bancorp+286
- FMR LLC (Fidelity)−12.00M
Source: 13F-HR filings on SEC EDGAR (aggregated from 181 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
AVIR filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 19, 2026 | - | - | - |
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 8-K | Nov 9, 2026 | - | Analysis | - |
| 10-Q | Nov 9, 2026 | Sep 30, 2026 | Analysis | |
| 8-K | Aug 12, 2026 | - | Analysis | - |
| 10-Q | Aug 12, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 4 | Jun 23, 2026 | - | - | - |
| 8-K | Jun 22, 2026 | - | Analysis | - |
| 4 | May 21, 2026 | - | - | |
| 4 | May 20, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 12, 2026 | - | Analysis | |
| 4 | Mar 13, 2026 | - | - | - |
| 10-K | Mar 5, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 5, 2026 | - | Analysis | - |
| SC 13G | Feb 9, 2026 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
AVIR SEC filings: frequently asked questions
Are AVIR insiders buying or selling?
In the last 90 days, Atea Pharmaceuticals, Inc. (AVIR) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $319,804 by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold AVIR stock?
As of September 30, 2026, the largest Atea Pharmaceuticals, Inc. (AVIR) holders among the 13F filers tracked by SignalX were BlackRock ($47.2 million), Vanguard Capital Management LLC ($15.1 million), State Street Corp ($8.5 million), Two Sigma Investments ($6.8 million), Dimensional Fund Advisors ($6.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What did AVIR report in its latest 8-K?
Atea Pharmaceuticals, Inc. (AVIR) filed an 8-K on November 9, 2026 reporting Item 2.03 (Creation of a Direct Financial Obligation) and Item 1.01 (Entry into a Material Definitive Agreement). Item 2.03 points to Item 1.01 for details on Atea’s newly created financial obligation.
What are the latest AVIR SEC filings?
Atea Pharmaceuticals, Inc. (AVIR) filed its latest 10-K annual report on March 5, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 9, 2026 and a Form 4 insider filing on November 19, 2026.
What is AVIR's SEC CIK number?
Atea Pharmaceuticals, Inc. (AVIR)'s SEC Central Index Key (CIK) is 1593899. EDGAR lists every AVIR filing under that number.
Ask anything about AVIR
The research agent reads AVIR's filings, financials, insider trades and 13F holders, then answers with sources.